SEARCH

SEARCH BY CITATION

References

  • 1
    National Board of Health and Welfare. Kvalitet och effektivitet – Jämförelser mellan landsting (Comparisons of the quality and productivity between county councils) 2012.
  • 2
    Mattsson P, Tomson T, Eriksson Ö, Brännström L. Ringbäck Weitoft G. Sociodemographic differences in antiepileptic drug prescriptions to adult epilepsy patients. Neurology 2010;74:295301.
  • 3
    Gustavsson A, Svensson M, Jacobi F et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:71879.
  • 4
    Medical Products Agency (Läkemedelsverket). Läkemedelsbehandling av epilepsi – Bakgrundsdokumentation (Pharmaceutical treatment of epilepsy – a documentation). 2011.
  • 5
    Bolin K, Lundgren A, Berggren F, Källén K. Epilepsy in Sweden: healthcare costs and loss of productivity – a register-based approach. Eur J Health Econ 2012;13:81926.
  • 6
    Lindgren B. Costs of Illness in Sweden 1964–1975. Lund University Economics Department, Lund, Sweden, 1981 (diss).
  • 7
    Rice DP. Estimating the Cost of Illness. Health economic series no. 6. Public Health Service. Washington, DC: US Government Printing Office, 1966.
  • 8
    Thurman DJ, Beghi E, Begley CE et al. Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia 2011;52(Suppl 7):226.
  • 9
    Bolin K, Berggren F, Landtblom AM. Prevalence and cost of epilepsy in Sweden – a register-based approach. Acta Neurol Scand, forthcoming.
  • 10
    Giuliani G, Terziani S, Senigaglia AR et al. Epilepsy in an Italian community as assessed by a survey for prescriptions of antiepileptic drugs: epidemiology and patterns of care. Acta Neurol Scand 1992;85:2331.
  • 11
    Strzelczyk A, Haag A, Reese JP et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany. Epilepsy Behav 2013;27:4338.
  • 12
    Strzelczyk A, Nickolay T, Bauer S et al. Evaluation of health-care utilization among adult patients with epilepsy in Germany. Epilepsy Behav 2012;23:4517.
  • 13
    de Zelicourt M, de Toffol B, Vespignani H, Laurendeau C et al. Management of focal epilepsy in adults treated with polytherapy in France: the direct cost of drug resistance (ESPERA study). Seizure 2014;23(5):34956.
  • 14
    Jennum P, Gyllenborg J, Kjellberg J. The social and economic consequences of epilepsy: a controlled national study. Epilepsia 2011;52:94956.